Graves’ disease, an autoimmune trigger of hyperthyroidism, arises from thyroid-stimulating immunoglobulins (TSI) that bind the TSH receptor (TSHR), relentlessly stimulating thyroid cells to overproduce hormones. Without a cure, the disease is controlled with antithyroid drugs that block hormone production. Yet, the source of these autoantibodies, which mimic TSH to drive hyperthyroidism, remains elusive.
Our innovative research focuses on whether DE cells are the source of these disease-causing antibodies, a pathway we are determined to explore for the development of future cures. Pinpointing this source could unlock the development of specific, targeted treatments.
